Abstract
In patients suffering from systemic sclerosis (SSc), pulmonary arterial hypertension (PAH) is a life-threatening complication linked to immune dysregulation. Preclinical analyses in Fos-related antigen-2 (Fra-2) transgenic (TG) mice, a model of SSc-PAH, identify type 2 inflammation as a key driver of vascular remodeling. Anti-inflammatory treatment targeting type 2 inflammation via IL-13 neutralizing antibodies improved pulmonary vascular remodeling. Thus, type 2-specific anti-inflammatory treatment may be a promising therapeutic approach in SSc-PAH.
Funding Information
  • Deutsche Forschungsgemeinschaft (SFB1449 and SFB-TR84)
  • Austrian Science Fund (T1032-B34)
  • European Respiratory Society (STRTF 2015 - 9543)
  • Austrian Science Fund (KLI 884-B)

This publication has 63 references indexed in Scilit: